Anixa Biosciences has scored a major step in the race to create a preventive breast cancer vaccine. The company now holds its first Australian composition-of-matter patent, giving it exclusive rights in Australia until 2040. This comes as Anixa builds on positive Phase 1 trial results and pushes ahead with more clinical work.
Anixa has also secured a South Korean patent for its breast cancer vaccine technology, with protection extending through 2040.
This patent is not just another filing. It follows real clinical results. In a completed Phase 1 trial at Cleveland Clinic, funded by the U.S. Department of Defense, the vaccine met all main safety and immune response goals. Over 74% of participants showed the expected immune response. The vaccine was safe and well tolerated. These results do not mean the vaccine is approved yet, but they set the stage for Anixa’s next clinical steps and possible global partnerships. As a PR Newswire release notes, there are still no approved preventive breast cancer vaccines anywhere in the world.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, said the expanded patent estate gives the company more leverage to seek regulatory approvals and business deals worldwide. The patent lists Dr. Justin Johnson and the late Dr. Vincent Tuohy of Cleveland Clinic as co-inventors, showing the ongoing partnership between Anixa and top research centers.
Anixa continues to frame its breast cancer vaccine program as advancing toward Phase 2 development, emphasizing that the expanded patent estate will support regulatory filings and commercialization efforts worldwide.
With the Australian patent secured, Anixa is protecting its science and setting up for future regulatory filings, new partnerships, and commercial launches. The company’s business model relies on working with groups like Cleveland Clinic and Moffitt Cancer Center. This lets Anixa keep testing and moving forward with new immunotherapy ideas for different cancers.
Anixa’s S-3 shelf registration is still unused, and the company’s stock only saw a small bump before the patent news. The bigger story is how Anixa is building a global patent wall that could shape the market for years. The patent does not mean the vaccine is approved, but it shows Anixa is betting on the future of cancer prevention. If the vaccine keeps showing results in trials, Anixa could change how breast cancer is prevented and managed around the world.
